ClinicalTrials.gg
CompletedNCT01189201Updated Mar 19, 2015Results posted

Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

A Phase 1 interventional study of BI 10773/linagliptin and BI 10773/linagliptin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-19.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary objective of the current study is to investigate the relative bioavailability of BI 10773 / linagliptin fixed dose combination tablet (formulation A1, Treatment A, Test) compared to BI 10773 given in free combination with linagliptin (Treatment B, Reference), both in the fasting state. All 42 subjects entered are planned to be included in this comparison.

The secondary objective is to investigate the relative bioavailability of BI 10773 / linagliptin fixed dose combination tablet after administration of a standardised high fat, high caloric meal (formulation A1, Treatment C, Test) compared to BI 10773 / linagliptin fixed dose combination in the fasting state (formulation A1,Treatment A, Reference). Of the 42 subjects entered 18 subjects are planned to be included in this comparison.

An additional objective is to investigate the relative bioavailability of a second formulation of the fixed dose combination tablet of BI 10773 / linagliptin (formulation A3,Treatment D, Test) compared to BI 10773 / linagliptin fixed dose combination tablet (formulation A1,Treatment A, Reference). Of the 42 subjects entered 24 subjects are planned to be included in this comparison.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria:

healthy male and female subjects

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    BI 10773/linagliptin FDC SID

    medium single dose ofBI 10773/linagliptin FDC (Formulation A1)

    Drug: BI 10773/linagliptin

  • Experimental
    BI 10773/linagliptin SID

    medium single dose of mono components BI 10773/linagliptin

    Drug: BI 10773/linagliptin SID

  • Experimental
    BI 10773/linagliptin FDC

    medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal

    Drug: BI 10773/linagliptin FDC

  • Experimental
    BI 10773/linagliptin

    medium single dose of BI 10773/linagliptin FDC (Formulation A3)

    Drug: BI 10773/linagliptin

Interventions

06

What researchers measure

Primary outcomes

  1. Empagliflozin: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)

    Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  2. Linagliptin: Area Under the Curve 0 to 72 Hours (AUC0-72)

    Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  3. Empagliflozin: Maximum Measured Concentration (Cmax)

    Maximum measured concentration of empagliflozin (empa) in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  4. Linagliptin: Maximum Measured Concentration (Cmax)

    Maximum measured concentration of linagliptin in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  5. Empagliflozin Fed vs Fasted: Maximum Measured Concentration (Cmax)

    Maximum measured concentration of empagliflozin (empa) in plasma, comparing fed with fasted. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  6. Empagliflozin Fed vs Fasted: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)

    Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  7. Linagliptin Fed vs Fasted: Maximum Measured Concentration (Cmax)

    Maximum measured concentration of linagliptin in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  8. Linagliptin Fed vs Fasted: Area Under the Curve 0 to 72 Hours (AUC0-72)

    Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  9. Empagliflozin Formulation Comparison: Maximum Measured Concentration (Cmax)

    Maximum measured concentration of empagliflozin (empa) in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  10. Empagliflozin Formulation Comparison: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)

    Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  11. Linagliptin Formulation Comparison: Maximum Measured Concentration (Cmax)

    Maximum measured concentration of linagliptin in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  12. Linagliptin Formulation Comparison: Area Under the Curve 0 to 72 Hours (AUC0-72)

    Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

Secondary outcomes

  1. Empagliflozin: Time From Last Dosing to Maximum Measured Concentration (Tmax)

    Time from last dosing to the maximum measured concentration of empagliflozin (empa) in plasma.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  2. Linagliptin: Time From Last Dosing to Maximum Measured Concentration (Tmax)

    Time from last dosing to the maximum measured concentration of linagliptin in plasma

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  3. Empagliflozin: Area Under the Curve 0 to Infinity (AUC0-∞)

    Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  4. Linagliptin: Area Under the Curve 0 to Infinity (AUC0-∞)

    Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  5. Empagliflozin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞)

    Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  6. Linagliptin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞)

    Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  7. Empagliflozin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞)

    Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  8. Linagliptin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞)

    Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration

  9. Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator

    Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator. New abnormal findings or worsening of baseline conditions were reported as Adverse Events. Time frame for adverse event was until the end-of-study examination.

    Time frame: Drug administration until next treatment period/end-of-study examination, up to 36 days

07

Results

Posted Mar 19, 2015

Participant flow

Participant flow — Overall Study
MilestoneStudy Overall
Started42
Received empa/linagliptin fdc a1(fasted)42
Rec. empa/linagliptin ind.tablet(fasted)41
Received empa/linagliptin fdc a1 (fed)18
Received empa/linagliptin fdc a3(fasted)24
Completed41
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryEmpagliflozin: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)

Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Empagliflozin: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)
nmol*h/LEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin Individual Tablets (Fasted)
Empagliflozin: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)5990 ± 21.05720 ± 20.8
Statistical analysis
  • Empa Plus Linagliptin FDC A1 (Fasted) vs Empa Plus Linagliptin Individual Tablets (Fasted) · ANOVA · Geometric mean ratio: 104.90 · 90% CI 102.07 to 107.80Standard deviation is actually the geometric coefficient of variation (gCV)
PrimaryLinagliptin: Area Under the Curve 0 to 72 Hours (AUC0-72)

Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Linagliptin: Area Under the Curve 0 to 72 Hours (AUC0-72)
nmol*h/LEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin Individual Tablets (Fasted)
Linagliptin: Area Under the Curve 0 to 72 Hours (AUC0-72)264 ± 22.1250 ± 22.1
Statistical analysis
  • Empa Plus Linagliptin FDC A1 (Fasted) vs Empa Plus Linagliptin Individual Tablets (Fasted) · ANOVA · Geometric mean ratio: 104.91 · 90% CI 99.97 to 110.09Standard deviation is actually the gCV
PrimaryEmpagliflozin: Maximum Measured Concentration (Cmax)

Maximum measured concentration of empagliflozin (empa) in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Geometric mean · nmol/L
Empagliflozin: Maximum Measured Concentration (Cmax)
nmol/LEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin Individual Tablets (Fasted)
Empagliflozin: Maximum Measured Concentration (Cmax)862 ± 26.8803 ± 24.9
Statistical analysis
  • Empa Plus Linagliptin FDC A1 (Fasted) vs Empa Plus Linagliptin Individual Tablets (Fasted) · ANOVA · Geometric mean ratio: 107.68 · 90% CI 101.70 to 114.02Standard deviation is actually the gCV
PrimaryLinagliptin: Maximum Measured Concentration (Cmax)

Maximum measured concentration of linagliptin in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Geometric mean · nmol/L
Linagliptin: Maximum Measured Concentration (Cmax)
nmol/LEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin Individual Tablets (Fasted)
Linagliptin: Maximum Measured Concentration (Cmax)8.19 ± 36.47.49 ± 31.0
Statistical analysis
  • Empa Plus Linagliptin FDC A1 (Fasted) vs Empa Plus Linagliptin Individual Tablets (Fasted) · ANOVA · Geometric mean ratio: 109.68 · 90% CI 99.55 to 120.83Standard deviation is actually the gCV
SecondaryEmpagliflozin: Time From Last Dosing to Maximum Measured Concentration (Tmax)

Time from last dosing to the maximum measured concentration of empagliflozin (empa) in plasma.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Median · hours
Empagliflozin: Time From Last Dosing to Maximum Measured Concentration (Tmax)
hoursEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin Individual Tablets (Fasted)Empa Plus Linagliptin FDC A1 (Fed)Empa Plus Linagliptin FDC A3 (Fasted)
Empagliflozin: Time From Last Dosing to Maximum Measured Concentration (Tmax)1.50 (0.67 to 4.00)1.25 (0.67 to 3.98)2.00 (0.67 to 4.00)1.50 (0.67 to 3.00)
SecondaryLinagliptin: Time From Last Dosing to Maximum Measured Concentration (Tmax)

Time from last dosing to the maximum measured concentration of linagliptin in plasma

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Median · hours
Linagliptin: Time From Last Dosing to Maximum Measured Concentration (Tmax)
hoursEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin Individual Tablets (Fasted)Empa Plus Linagliptin FDC A1 (Fed)Empa Plus Linagliptin FDC A3 (Fasted)
Linagliptin: Time From Last Dosing to Maximum Measured Concentration (Tmax)1.50 (0.33 to 6.03)1.75 (0.67 to 10.0)2.25 (1.00 to 4.00)1.50 (0.33 to 4.00)
SecondaryEmpagliflozin: Area Under the Curve 0 to Infinity (AUC0-∞)

Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Empagliflozin: Area Under the Curve 0 to Infinity (AUC0-∞)
nmol*h/LEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin Individual Tablets (Fasted)
Empagliflozin: Area Under the Curve 0 to Infinity (AUC0-∞)6060 ± 20.75800 ± 20.9
Statistical analysis
  • Empa Plus Linagliptin FDC A1 (Fasted) vs Empa Plus Linagliptin Individual Tablets (Fasted) · ANOVA · Geometric mean ratio: 104.78 · 90% CI 102.02 to 107.61Standard deviation is actually the gCV
SecondaryLinagliptin: Area Under the Curve 0 to Infinity (AUC0-∞)

Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Linagliptin: Area Under the Curve 0 to Infinity (AUC0-∞)
nmol*h/LEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin Individual Tablets (Fasted)
Linagliptin: Area Under the Curve 0 to Infinity (AUC0-∞)435 ± 26.5410 ± 29.8
Statistical analysis
  • Empa Plus Linagliptin FDC A1 (Fasted) vs Empa Plus Linagliptin Individual Tablets (Fasted) · ANOVA · Geometric mean ratio: 104.64 · 90% CI 97.23 to 112.62Standard deviation is actually the gCV
SecondaryEmpagliflozin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞)

Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Empagliflozin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞)
nmol*h/LEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin FDC A1 (Fed)
Empagliflozin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞)6410 ± 16.05500 ± 16.8
Statistical analysis
  • Empa Plus Linagliptin FDC A1 (Fasted) vs Empa Plus Linagliptin FDC A1 (Fed) · ANOVA · Geometric mean ratio: 85.86 · 90% CI 81.33 to 90.64Standard deviation is actually the gCV
PrimaryEmpagliflozin Fed vs Fasted: Maximum Measured Concentration (Cmax)

Maximum measured concentration of empagliflozin (empa) in plasma, comparing fed with fasted. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Geometric mean · nmol/L
Empagliflozin Fed vs Fasted: Maximum Measured Concentration (Cmax)
nmol/LEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin FDC A1 (Fed)
Empagliflozin Fed vs Fasted: Maximum Measured Concentration (Cmax)949 ± 23.7583 ± 21.7
Statistical analysis
  • Empa Plus Linagliptin FDC A1 (Fasted) vs Empa Plus Linagliptin FDC A1 (Fed) · ANOVA · Geometric mean ratio: 61.41 · 90% CI 54.10 to 69.71Standard deviation is actually the gCV
PrimaryEmpagliflozin Fed vs Fasted: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)

Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Empagliflozin Fed vs Fasted: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)
nmol*h/LEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin FDC A1 (Fed)
Empagliflozin Fed vs Fasted: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)6330 ± 16.45400 ± 16.3
Statistical analysis
  • Empa Plus Linagliptin FDC A1 (Fasted) vs Empa Plus Linagliptin FDC A1 (Fed) · ANOVA · Geometric mean ratio: 85.32 · 90% CI 80.77 to 90.14Standard deviation is actually the gCV
SecondaryLinagliptin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞)

Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Linagliptin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞)
nmol*h/LEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin FDC A1 (Fed)
Linagliptin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞)453 ± 24.2421 ± 19.0
Statistical analysis
  • Empa Plus Linagliptin FDC A1 (Fasted) vs Empa Plus Linagliptin FDC A1 (Fed) · ANOVA · Geometric mean ratio: 93.18 · 90% CI 85.07 to 102.05Standard deviation is actually the gCV
PrimaryLinagliptin Fed vs Fasted: Maximum Measured Concentration (Cmax)

Maximum measured concentration of linagliptin in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Geometric mean · nmol/L
Linagliptin Fed vs Fasted: Maximum Measured Concentration (Cmax)
nmol/LEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin FDC A1 (Fed)
Linagliptin Fed vs Fasted: Maximum Measured Concentration (Cmax)8.97 ± 40.06.14 ± 17.0
Statistical analysis
  • Empa Plus Linagliptin FDC A1 (Fasted) vs Empa Plus Linagliptin FDC A1 (Fed) · ANOVA · Geometric mean ratio: 68.48 · 90% CI 58.59 to 80.03Standard deviation is actually the gCV
PrimaryLinagliptin Fed vs Fasted: Area Under the Curve 0 to 72 Hours (AUC0-72)

Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Linagliptin Fed vs Fasted: Area Under the Curve 0 to 72 Hours (AUC0-72)
nmol*h/LEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin FDC A1 (Fed)
Linagliptin Fed vs Fasted: Area Under the Curve 0 to 72 Hours (AUC0-72)275 ± 21.7250 ± 19.2
Statistical analysis
  • Empa Plus Linagliptin FDC A1 (Fasted) vs Empa Plus Linagliptin FDC A1 (Fed) · ANOVA · Geometric mean ratio: 90.95 · 90% CI 84.24 to 98.19Standard deviation is actually the gCV
SecondaryEmpagliflozin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞)

Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Empagliflozin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞)
nmol*h/LEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin FDC A3 (Fasted)
Empagliflozin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞)5810 ± 23.15560 ± 20.8
Statistical analysis
  • Empa Plus Linagliptin FDC A1 (Fasted) vs Empa Plus Linagliptin FDC A3 (Fasted) · ANOVA · Geometric mean ratio: 95.64 · 90% CI 91.19 to 100.30Standard deviation is actually the gCV
PrimaryEmpagliflozin Formulation Comparison: Maximum Measured Concentration (Cmax)

Maximum measured concentration of empagliflozin (empa) in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Geometric mean · nmol/L
Empagliflozin Formulation Comparison: Maximum Measured Concentration (Cmax)
nmol/LEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin FDC A3 (Fasted)
Empagliflozin Formulation Comparison: Maximum Measured Concentration (Cmax)802 ± 27.0787 ± 25.2
Statistical analysis
  • Empa Plus Linagliptin FDC A1 (Fasted) vs Empa Plus Linagliptin FDC A3 (Fasted) · ANOVA · Geometric mean ratio: 98.04 · 90% CI 91.95 to 104.53Standard deviation is actually the gCV
PrimaryEmpagliflozin Formulation Comparison: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)

Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Empagliflozin Formulation Comparison: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)
nmol*h/LEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin FDC A3 (Fasted)
Empagliflozin Formulation Comparison: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)5740 ± 23.35490 ± 21.1
Statistical analysis
  • Empa Plus Linagliptin FDC A1 (Fasted) vs Empa Plus Linagliptin FDC A3 (Fasted) · ANOVA · Geometric mean ratio: 95.69 · 90% CI 91.17 to 100.43Standard deviation is actually the gCV
SecondaryLinagliptin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞)

Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Linagliptin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞)
nmol*h/LEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin FDC A3 (Fasted)
Linagliptin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞)423 ± 28.3393 ± 33.8
Statistical analysis
  • Empa Plus Linagliptin FDC A1 (Fasted) vs Empa Plus Linagliptin FDC A3 (Fasted) · ANOVA · Geometric mean ratio: 92.98 · 90% CI 86.36 to 100.09Standard deviation is actually the gCV
PrimaryLinagliptin Formulation Comparison: Maximum Measured Concentration (Cmax)

Maximum measured concentration of linagliptin in plasma. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Geometric mean · nmol/L
Linagliptin Formulation Comparison: Maximum Measured Concentration (Cmax)
nmol/LEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin FDC A3 (Fasted)
Linagliptin Formulation Comparison: Maximum Measured Concentration (Cmax)7.65 ± 32.77.93 ± 33.5
Statistical analysis
  • Empa Plus Linagliptin FDC A1 (Fasted) vs Empa Plus Linagliptin FDC A3 (Fasted) · ANOVA · Geometric mean ratio: 103.71 · 90% CI 92.93 to 115.74Standard deviation is actually the gCV
PrimaryLinagliptin Formulation Comparison: Area Under the Curve 0 to 72 Hours (AUC0-72)

Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours. In this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Linagliptin Formulation Comparison: Area Under the Curve 0 to 72 Hours (AUC0-72)
nmol*h/LEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin FDC A3 (Fasted)
Linagliptin Formulation Comparison: Area Under the Curve 0 to 72 Hours (AUC0-72)256 ± 22.4247 ± 26.3
Statistical analysis
  • Empa Plus Linagliptin FDC A1 (Fasted) vs Empa Plus Linagliptin FDC A3 (Fasted) · ANOVA · Geometric mean ratio: 96.36 · 90% CI 89.78 to 103.42Standard deviation is actually the gCV
SecondaryClinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator

Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator. New abnormal findings or worsening of baseline conditions were reported as Adverse Events. Time frame for adverse event was until the end-of-study examination.

Time frame:
Drug administration until next treatment period/end-of-study examination, up to 36 days
Reported as:
Number · participants
Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator
participantsEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin Indivdual Tablets (Fasted)Empa Plus Linagliptin FDC A1 (Fed)Empa Plus Linagliptin FDC A3 (Fasted)
Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator0000

Adverse events

Collected over Treatment period and following washout period, up to 36 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Empa Plus Linagliptin FDC A1 (Fasted)—0/42 (0%)8/42 (19%)
Empa Plus Linagliptin Individual Tablets (Fasted)—0/41 (0%)5/41 (12.2%)
Empa Plus Linagliptin FDC A1 (Fed)—0/18 (0%)6/18 (33.3%)
Empa Plus Linagliptin FDC A3 (Fasted)—0/24 (0%)4/24 (16.7%)
Most frequent other events
Most frequent other events
EventEmpa Plus Linagliptin FDC A1 (Fasted)Empa Plus Linagliptin Individual Tablets (Fasted)Empa Plus Linagliptin FDC A1 (Fed)Empa Plus Linagliptin FDC A3 (Fasted)
NasopharyngitisInfections and infestations1/421/413/180/24
HeadacheNervous system disorders4/424/411/182/24
Abdominal painGastrointestinal disorders0/420/411/181/24
NauseaGastrointestinal disorders2/420/411/181/24
VomitingGastrointestinal disorders2/422/411/181/24
Back painMusculoskeletal and connective tissue disorders1/420/411/180/24
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/420/411/180/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)Study Overall
Mean40.3 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Study Overall
Female25
Male17
08

Study locations

1 site
  • 1275.3.1 Boehringer Ingelheim Investigational Site
    Biberach, Germany
09

References and documents

Publications

  • Glund S, Mattheus M, Runge F, Rose P, Friedrich C. Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet . Int J Clin Pharmacol Ther. 2017 Apr;55(4):355-367. doi: 10.5414/CP202929. PubMed 28290274 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010 and a primary completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 4 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2010
First posted
Aug 26, 2010
Start
Aug 2010
Primary completionActual
Nov 2010
Results first posted
Mar 19, 2015
Last update
Mar 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01189201
Responsible party
Sponsor
First posted
Aug 26, 2010
Start date
Aug 2010
Primary completion
Nov 2010
Results posted
Mar 19, 2015
Last update
Mar 19, 2015

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Linagliptin

Start the discussion